



For Immediate Release:

Date: September 17, 2009

Contacts:

Dr. Andrew Fox
President & Founder
Wadsworth Medical Technologies
Cell: 508-789-6531
afox@wadsworthmedical.com

Angus McQuilken
Vice President for Communications
Massachusetts Life Sciences Center
Cell: 617-921-7749
amcquilken@masslifesciences.com

Wadsworth Medical Technologies Announces FDA Approval of DermaLOC

Westborough, MA – Wadsworth Medical Technologies today announced approval by the U.S. Food and Drug Administration (FDA) for DermaLOC, a non-invasive, needleless wound closure system. DermaLOC is officially classified by the FDA as a Class I Device that presents minimal risk to the user. This classification will allow Wadsworth Medical Technologies to market DermaLOC for human use.

“We are pleased by DermaLOC’s FDA pathway and approval,” says Dr. Andrew Fox, President & Founder of Wadsworth Medical Technologies. “This is in concert with our company’s mission – to develop and market innovative but simple products for patients and practitioners.”

In April of 2009, Wadsworth Medical Technologies received a \$400,000 Accelerator Loan from the Massachusetts Life Sciences Center, a quasi-public agency tasked with implementing Massachusetts’ ten-year, \$1 billion Life Sciences Initiative. The Accelerator Loan Program provided \$3.4 million in working capital to seven early-stage life sciences companies, including Wadsworth.

“The FDA’s approval of Wadsworth Medical Technologies’ DermaLOC wound closure system demonstrates that the Massachusetts Life Sciences Center is committed to promoting good science that will bring commercialization and job growth to Massachusetts,” said Dr. Susan Windham-Bannister, President & CEO of the Massachusetts Life Sciences Center. “We are very proud to have Wadsworth as part of our investment portfolio.”

About Wadsworth Medical Technologies

Wadsworth Medical Technologies is a Massachusetts-based medical device company targeting the wound closure market. Wadsworth uses next generation adhesives combined with intelligent engineering to form a painless system which can be rapidly placed with optimal healing results. Its lead product, DermaLOC Wound Closure System®, applies tension to skin wounds to close them without anesthesia or sutures resulting in a novel, painless, rapid, needleless and durable wound closure.

About the Massachusetts Life Sciences Center

The Massachusetts Life Sciences Center is a quasi-public agency of the Commonwealth of Massachusetts tasked with implementing the Massachusetts Life Sciences Act, a ten-year, \$1 billion initiative that was signed into law in June of 2008. The Center's mission is to create jobs in the life sciences and support vital scientific research that will improve the human condition. This work includes making financial investments in public and private institutions that are advancing life sciences research, development and commercialization as well as building ties between sectors of the Massachusetts life sciences community. For more information, visit www.masslifesciences.com.

About the Life Sciences Accelerator

In order to expand life sciences-related employment opportunities, promote health-related innovations and stimulate research and development, manufacturing and commercialization in the life sciences, the Life Sciences Accelerator Program provides loans to companies engaged in life sciences research and development, commercialization and manufacturing in Massachusetts. Target entities are generally early-stage life sciences companies with a high-potential for technology commercialization, rapid growth, and downstream private equity financing. The program is designed to help sustain these companies through a critical stage of development and to leverage additional sources of capital to bring cutting edge innovation to the marketplace. Accordingly, the Program places special priority on providing matching funds for grants or awards from a variety of sources.

###